Stumbles Wound FDA’s Reputation as Review of Vaccine Nears
- Agency prepares to review Covid-19 vaccines in coming months
- FDA chief Hahn says he’s worried about impact on perception
Stephen Hahnspeaks during a news conference in the James S. Brady Press Briefing Room at the White House in Washington D.C., U.S., on Aug. 23.
Photographer: Stefani Reynolds/BloombergThis article is for subscribers only.
First, it was President Donald Trump accusing the agency of being part of the “deep state.” Next, it was an embarrassing misstatement about a promising Covid-19 therapy. On Friday, the agency’s new lead spokeswoman was ousted after just 11 days.
It has not been a good week for the U.S. Food and Drug Administration.